E-viri
Recenzirano
-
YVES GAUTHIER, Jacques; BELLEY, Michel; LAVALLEE, Geneviève; LEVESQUE, Jean-François; LIANHAI LI; MAMANE, Yael; MANCINI, Joseph; MORIN, Nicolas; MULROONEY, Erin; ROBICHAUD, Joel; THERIEN, Michel; TRANMER, Geoffrey; DESCHENES, Denis; ZHAOYIN WANG; JIN WU; BLACK, W. Cameron; FOURNIER, Jean-François; GAGNE, Sébastien; GAREAU, Yves; HAMEL, Martine; HENAULT, Martin; HYJAZIE, Huda; KARGMAN, Stacia
Bioorganic & medicinal chemistry letters, 05/2011, Letnik: 21, Številka: 10Journal Article
A weak, UDP-competitive antagonist of the pyrimidinergic receptor P2RY(14) with a naphthoic acid core was identified through high-throughput screening. Optimization provided compounds with improved potency but poor pharmacokinetics. Acylglucuronidation was determined to be the major route of metabolism. Increasing the electron-withdrawing nature of the substituents markedly reduced glucuronidation and improved the pharmacokinetic profile. Additional optimization led to the identification of compound 38 which is an 8 nM UDP-competitive antagonist of P2Y(14) with a good pharmacokinetic profile.
